ClinicalTrials.gg
CompletedNCT00045864Updated Feb 6, 2006

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

A Phase 2 interventional study of Recombinant Human Interleukin-2 and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Chiron Corporation. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-02-06.

Sponsored by Chiron Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 140 open to participants now, 255 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Phase 2
515 of 1,599
34 open now
Registered
253rd of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is one of 515 in phase 2, and was the 253rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

140 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

135 more — sign in →

All 140 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Intermediate and High-Grade Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or disease after no more than three prior chemotherapy regimens.

Exclusion criteria

Exclusion:

  • cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment
  • Clinically significant pulmonary dysfunction.
  • Liver disease (note seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment).
  • Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.
  • History of disease.
  • History of positive serology for (HIV).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment

Interventions

06

Study locations

33 sites
  • ACRC/Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85712, United States
  • Hoag Cancer Center
    Newport Beach, California 92658, United States
  • UC Davis Cancer Center
    Sacramento, California 95817, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • Stanford University Medical Center
    Stanford, California 94305-5151, United States
  • California Cancer Medical Center
    West Covina, California 91790, United States
  • Georgetown University Medical Center, Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Washington Cancer Institute
    Washington, District of Columbia 20010, United States
  • Division of Hematology/Oncology, University of Miami School of Medicine
    Miami, Florida 333136, United States
  • Northwestern University, Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush Cancer Institute
    Chicago, Illinois 60612, United States
  • Oncology Specialists, S.C.
    Park Ridge, Illinois 60068, United States
  • Cancer Care Center
    Bloomington, Indiana 47403, United States
  • Consultants in Blood Disorders and Cancer
    Louisville, Kentucky 40207, United States
  • Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology
    Shreveport, Louisiana 71130, United States
  • Kansas City Oncology and Hematology Group
    Kansas City, Missouri 64111, United States
  • Arch Medical Group, LLC
    St. Louis, Missouri 63141, United States
  • Dartmouth-Hitchcock-Medical Center
    Lebanon, New Hampshire 03756, United States
  • Our Lady of Mercy Medical Center, Comprehensive Cancer Center
    Bronx, New York 10466, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • East Carolina University School of Medicine/ Division of Hematology/Oncology
    Greenville, North Carolina 27858, United States
  • Roger Maris Health System
    Fargo, North Dakota 58122, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Oncology Hematology Care Inc.
    Cincinnati, Ohio 45242, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Hematology /Oncology Consultants Inc.
    Columbus, Ohio 43235, United States
  • Oregon Heath and Science University
    Portland, Oregon 97201, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29615, United States
  • Germantown Cancer Center
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Cancer Specialists of South Texas, P.A.
    Corpus Christi, Texas 78412, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00045864
Lead sponsor
Chiron Corporation
First posted
Sep 16, 2002
Last update
Feb 6, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aldesleukin · Interleukin-2 · Rituximab

Start the discussion